Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2018

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms LAVOLTA II
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 23 May 2018 Results of a post-hoc analysis from NCT01867125 and NCT01868061 studies presented at the 114th International Conference of the American Thoracic Society.
    • 08 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 23 Feb 2017 Results (n=2149) of pooled post hoc analysis of LAVOLTA I and LAVOLTA II trials assessing association between seasonal variability and clinical response of lebrikizumab, published in the Journal of Allergy and Clinical Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top